Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China-Reference-Cited by-同舟云学术

Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China

Published:2024-05-31 Issue:6 Volume:316 Page:
ISSN:1432-069X
Container-title:Archives of Dermatological Research
language:en
Short-container-title:Arch Dermatol Res

Author:

Deng Sisi,Wang Huan,Chen Qiquan,Chen Xueqin,Song Xiao,Chen Shuguang,Kong Minmin,Song Zhiqiang

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00403-024-03029-6.pdf

Reference25 articles.

1. Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA, Dupilumab (2018) A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 78(3 Suppl 1):S28–s36

2. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389(10086):2287–2303

3. Olesen CM, Holm JG, Nørreslet LB, Serup JV, Thomsen SF, Agner T (2019) Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol 33(8):1562–1568

4. Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek J, Kamsteeg M, Boesjes CM et al (2022) Dupilumab Drug Survival and Associated Predictors in patients with moderate to severe atopic dermatitis: long-term results from the Daily Practice BioDay Registry. JAMA Dermatol 158(9):1048–1056

5. Stölzl D, Sander N, Heratizadeh A, Haufe E, Harder I, Abraham S et al (2022) Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br J Dermatol 187(6):1022–1024